Drugmaker Johnson & Johnson has halted manufacturing of its single-dose COVID-19 vaccine, in keeping with a New York Occasions report.

The pharmaceutical firm final 12 months quietly shut down manufacturing at a plant in Leiden, Netherlands, which was the one facility the place usable doses of the vaccine have been manufactured, catching a few of its clients off guard, together with growing nations that desire the single-dose J&J drug over two-dose options, the report states. 

Johnson & Johnson has as a substitute been utilizing the plant to work on an experimental and probably extra worthwhile drug that might shield in opposition to an unrelated respiratory virus, in keeping with the report. 

The plant is predicted to renew manufacturing of the COVID-19 vaccine, however it’s unclear when. 

J&J didn’t touch upon the plant closure experiences, however stated in an announcement to CBS Information “we presently have hundreds of thousands of doses of our COVID-19 vaccine in stock” and “we proceed to meet our contractual obligations … [to] the African Union.” 

Vaccine of alternative for poorer nations

The J&J vaccine, referred to as the Janssen COVID-19 vaccine, made by Janssen Biotech, a subsidiary of Johnson & Johnson, is the vaccine of alternative for poorer nations which might be relying on the drugmaker to assist them struggle the pandemic. 

COVID deaths nonetheless rising as instances drop


Wealthier nations just like the U.S. have favored pictures from Moderna and Pfizer, as a result of the 2 look like more practical in opposition to COVID-19 variants like Omicron, and since the Janssen vaccine has, prior to now, been linked to uncommon however probably life-threatening blood clots. 

Provided that just one dose of the J&J vaccine is required, although, it is inexpensive than its double-dose counterparts and likewise simpler to ship, making it common in lower-income nations. 


Leave a Reply

Your email address will not be published.